长春高新：子公司注射用GenSci 143境外临床试验申请获FDA受理

Core Viewpoint - Changchun High-tech (000661.SZ) announced that its subsidiary, Jinsai Pharmaceutical, has received acceptance from the US FDA for the clinical trial application of GenSci143, a dual-specific antibody-drug conjugate targeting B7-H3 and PSMA [1] Group 1: Product Development - GenSci143 is independently developed by Jinsai Pharmaceutical and is designed to target both chemotherapy and tumor immunity, offering dual potential therapeutic effects [1] - The innovative dual-target design, stable linker technology, and efficient cell-killing mechanism of GenSci143 may provide new treatment options for various solid tumors expressing B7-H3 and/or PSMA [1] Group 2: Regulatory Milestones - The clinical trial application for GenSci143 intended for advanced solid tumors has also been accepted by the National Medical Products Administration in China, with a planned submission date in August 2025 [1]